Results 131 to 140 of about 82,297 (250)

Intensive versus standard dose statin therapy: the costs and benefits for patients with acute coronary syndrome [PDF]

open access: yes
Introduction: Recent NICE guidance in England and Wales states that statin therapy for secondary CVD should "usually be initiated with a drug with a low acquisition cost (taking into account required daily dose and product price per dose)".
Ara, R.   +3 more
core  

Intravenous Tolvaptan Sodium Phosphate Can Fail to Improve Fluid Overload Due to Heart Failure in Patients With Chronic Kidney Disease: A Case Report

open access: yesPharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT Tolvaptan is widely used as an adjunct oral diuretic to loop and thiazide diuretics for the management of fluid overload in patients with congestive heart failure. Recently, tolvaptan sodium phosphate (TSP), a water‐soluble prodrug of tolvaptan, was developed for intravenous administration and has demonstrated efficacy and safety in clinical ...
Takaya Uno   +10 more
wiley   +1 more source

Evaluating the Educational Value of Artificial Intelligence in Pharmacotherapy Education

open access: yesPharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT Final‐year medical students frequently make prescribing errors, partly because they have had insufficient training in therapeutic reasoning. Students need to understand the underlying rationale behind a drug choice in order to subsequently apply that knowledge critically and independently.
Mariëlle G. Hartjes   +4 more
wiley   +1 more source

Real‐World Patient Characteristics and Treatment Patterns Among Patients With Interstitial Cystitis (IC)/Bladder Pain Syndrome (BPS)

open access: yesReproductive, Female and Child Health, Volume 5, Issue 2, June 2026.
ABSTRACT Objective Interstitial cystitis/bladder pain syndrome (IC/BPS) is linked to bladder and/or pelvic pain, pressure, and discomfort with urinary frequency. Despite guidelines, there is a need for better treatment options. This study analyzed patient demographics, clinical characteristics, and treatment patterns for medications and procedures in ...
Jaromir Mikl   +8 more
wiley   +1 more source

Epicutaneous and Drug Provocation Testing in Severe Cutaneous Adverse Reactions: A 20‐Year Single‐Centre Experience

open access: yesContact Dermatitis, Volume 94, Issue 6, Page 677-688, June 2026.
This study provides reassuring evidence in favour of early skin testing in patients with SCARs, argues against the necessity of a 6‐month delay, and underscores the pivotal role of oral provocation tests in the safe reintroduction of essential therapies. ABSTRACT Background Identifying and discontinuing the offending drug(s) in severe cutaneous adverse
Zohra Chadli   +8 more
wiley   +1 more source

The development of type 2 diabetes amongst sibling pairs in the South‐South region of Nigeria: The effect of genetics, environment and lifestyle

open access: yesDiabetic Medicine, Volume 43, Issue 6, June 2026.
Abstract Introduction Type 2 diabetes is a complex condition with a multifactorial pathogenesis. The pathogenesis is considered to be polygenic due to complex interactions between genetic/epigenetic and environmental factors. The aim of this study is to determine the genetic, environmental and lifestyle factors associated with the development of type 2
Sunny Chinenye   +18 more
wiley   +1 more source

Evaluation of changes in the global longitudinal strain for left ventricular function before and after eight weeks of taking high dose of atorvastatin in patients with coronary slow flow phenomenon

open access: yesBMC Cardiovascular Disorders
Background Coronary Slow Flow Phenomenon (CSFP) is a well-recognized clinical entity characterized by delayed opacification of coronary arteries in the presence of a normal coronary angiogram.
Nakisa Khansari   +4 more
doaj   +1 more source

A Remote Chronic Disease Management Program to Improve Cardiovascular and Metabolic Outcomes in a Diverse Community‐Based Diabetic Population: Study Design of the TAMIS Trial

open access: yesJournal of Evaluation in Clinical Practice, Volume 32, Issue 4, June 2026.
ABSTRACT Introduction Cardiovascular and cerebrovascular diseases are projected to expand in the coming decades as the main cause of death. This study outlines the escalating burden of cardiovascular diseases in low‐ and middle‐income countries (LMICs), particularly in Latin America (LA), which is expected to surpass that of other high‐population ...
Renato de Carvalho Barros   +22 more
wiley   +1 more source

Simvastatin Restores Cisplatin Sensitivity by Suppressing the Caveolin‐1‐Mediated PI3K/AKT Signaling Pathway in Cisplatin‐Resistant Cervical Cancer Cells

open access: yesThe FASEB Journal, Volume 40, Issue 9, 15 May 2026.
Simvastatin synergizes with cisplatin in cisplatin‐resistant cervical cancer cells through suppression of the caveolin‐1‐mediated PI3K/AKT signaling axis. ABSTRACT Cervical cancer treatment is often hindered by the emergence of cisplatin (DDP) resistance. Increasing evidence has indicated that statins possess anti‐tumor and chemosensitization potential
Yujia Zhou   +7 more
wiley   +1 more source

Computational Modeling Meets 3D Bioprinting: Emerging Synergies in Cardiovascular Disease Modeling

open access: yesAdvanced Healthcare Materials, Volume 15, Issue 17, 8 May 2026.
Emerging advances in three‐dimensional bioprinting and computational modeling are reshaping cardiovascular (CV) research by enabling more realistic, patient‐specific tissue platforms. This review surveys cutting‐edge approaches that merge biomimetic CV constructs with computational simulations to overcome the limitations of traditional models, improve ...
Tanmay Mukherjee   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy